|
|
News Breaks | | | | October 18, 2012 | | 06:01 EDT |  | APRI | Apricus Biosciences receives $2.5M payment from Abbott Laboratories for Vitaros
Apricus Biosciences announced that it received a $2.5M payment from Abbott Laboratories Limited under its commercial partnership for Apricus Bio's Vitaros drug for erectile dysfunction, in Canada. Also, Apricus Bio successfully produced six consecutive commercial size validation batches of Vitaros, the company's treatment for ED in 220 mcg and 330 mcg forms. | |
|
News For APRI From The Last 14 Days Check below for free stories on APRI the last two weeks. |
|
|
| May 23, 2013 | | 08:42 EDT |  | APRI | Apricus Biosciences 6M share Spot Secondary priced at $2.85
 Subscribe for More Information | | | May 22, 2013 | | 18:52 EDT | | APRI | On The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 13.4% after reporting second quarter earnings that beat expectations and guiding third quarter and full-year earnings above estimates... Pacific Sunwear (PSUN), up 14.3%. ALSO HIGHER: Merck (MRK), up 0.2% after an FDA advisory panel voted 13-3 in support of the safety of initial doses of its insomnia drug suvorexant. DOWN AFTER EARNINGS: DryShips (DRYS), down 4.7%. ALSO LOWER: Apricus Biosciences (APRI), down 11.5% after filing to sell an ungiven amount of stock... NCI Building Systems (NCS) after being replaced by Cynosure (CYNO) in the S&P 600 as of May 31. | | | 16:03 EDT | | APRI | Apricus Biosciences files to sell common stock, no amount given
Lazard Capital Markets LLC is acting as sole book-running manager for the offering. | |
|
|
|
|
|
|
